GenMont Biotech Inc Market Cap ($46.47 Million)
Market Cap & Net Worth: GenMont Biotech Inc (3164)
GenMont Biotech Inc market cap. GenMont Biotech Inc (TW:3164) has a market capitalization of $46.47 Million (NT$1.48 Billion) as of November 4, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #21977 globally and #1360 in its home market, demonstrating a 0.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GenMont Biotech Inc's stock price NT$17.15 by its total outstanding shares 86010364 (86.01 Million). Also see how efficiently does GenMont Biotech Inc generate cash for how efficiently the company converts equity into cash flow.
GenMont Biotech Inc Market Cap History (2015–2026)
GenMont Biotech Inc market cap history from 2015 to 2026. Data shows change from $56.06 Million to $46.47 Million (-1.52% CAGR). Check 3164 stock price and chart for real-time trading data and today's change.
GenMont Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GenMont Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore GenMont Biotech Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.12x
GenMont Biotech Inc's market cap is 0.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.87x
GenMont Biotech Inc's market cap is 0.87 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $54.33 Million | $540.78 Million | -$235.94 Million | 0.10x | N/A |
| 2017 | $53.17 Million | $380.65 Million | $45.60 Million | 0.14x | 1.17x |
| 2018 | $61.72 Million | $406.53 Million | $158.02 Million | 0.15x | 0.39x |
| 2019 | $60.77 Million | $346.24 Million | $57.45 Million | 0.18x | 1.06x |
| 2020 | $56.40 Million | $325.19 Million | $60.88 Million | 0.17x | 0.93x |
| 2021 | $63.10 Million | $427.93 Million | $113.13 Million | 0.15x | 0.56x |
| 2022 | $64.22 Million | $368.55 Million | $56.98 Million | 0.17x | 1.13x |
| 2023 | $66.93 Million | $318.01 Million | $32.99 Million | 0.21x | 2.03x |
| 2024 | $54.74 Million | $385.37 Million | $57.25 Million | 0.14x | 0.96x |
| 2025 | $49.72 Million | $401.23 Million | $57.20 Million | 0.12x | 0.87x |
Competitor Companies of 3164 by Market Capitalization
Companies near GenMont Biotech Inc in the global market cap rankings as of November 4, 2026. Also see 3164 total assets for a full breakdown of the balance sheet.
Key companies related to GenMont Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of GenMont Biotech Inc (2015–2026)
Market capitalization of GenMont Biotech Inc from 2015 to today. Between 2015 and today, GenMont Biotech Inc's market cap moved from $56.06 Million to $ 46.47 Million, with a yearly change of -1.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$46.47 Million | -6.54% |
| 2025 | NT$49.72 Million | -9.16% |
| 2024 | NT$54.74 Million | -18.22% |
| 2023 | NT$66.93 Million | +4.22% |
| 2022 | NT$64.22 Million | +1.77% |
| 2021 | NT$63.10 Million | +11.88% |
| 2020 | NT$56.40 Million | -7.19% |
| 2019 | NT$60.77 Million | -1.54% |
| 2018 | NT$61.72 Million | +16.09% |
| 2017 | NT$53.17 Million | -2.13% |
| 2016 | NT$54.33 Million | -3.09% |
| 2015 | NT$56.06 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of GenMont Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.47 Million USD |
| MoneyControl | $46.47 Million USD |
| MarketWatch | $46.47 Million USD |
| marketcap.company | $46.47 Million USD |
| Reuters | $46.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. GenMont Biotech Incorporation was founded in 2000 and is based in Tainan … Read more